TUNICRIS-julkaisut - Trepo

Viitteet 1-1 / 1

Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study

Osterlund, P.; Kinos, S.; Pfeiffer, P.; Salminen, T.; Kwakman, J. J.M.; Frödin, J. E.; Shah, C. H.; Sorbye, H.; Ristamäki, R.; Halonen, P.; Soveri, L. M.; Heervä, E.; Ålgars, A.; Bärlund, M.; Hagman, H.; McDermott, R.; O'Reilly, M.; Röckert, R.; Liposits, G.; Kallio, R.; Flygare, P.; Teske, A. J.; van Werkhoven, E.; Punt, C. J.A.; Glimelius, B. (2022)
article

Background: Capecitabine- or 5-fluorouracil (5-FU)-based chemotherapy is widely used in many solid tumours, but is associated with cardiotoxicity. S-1 is a fluoropyrimidine with low rates of cardiotoxicity, but evidence ...